Literature DB >> 25149322

Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.

Christiane Auray-Blais1, Catherine-Marie Blais2, Uma Ramaswami3, Michel Boutin2, Dominique P Germain4, Sarah Dyack5, Olaf Bodamer6, Guillem Pintos-Morell7, Joe T R Clarke8, Daniel G Bichet9, David G Warnock10, Lucia Echevarria4, Michael L West5, Pamela Lavoie2.   

Abstract

BACKGROUND: Fabry disease is an X-linked lysosomal storage disorder affecting both males and females with tremendous genotypic/phenotypic variability. Concentrations of globotriaosylceramide (Gb3), globotriaosylsphingosine (lyso-Gb3)/related analogues were investigated in pediatric and adult Fabry cohorts. The aims of this study were to transfer and validate an HPLC-MS/MS methodology on a UPLC-MS/MS new generation platform, using an HPLC column, for urine analysis of treated and untreated pediatric and adult Fabry patients, to establish correlations between the excretion of Fabry biomarkers with gender, treatment, types of mutations, and to evaluate the biomarker reliability for early detection of pediatric Fabry patients.
METHOD: A UPLC-MS/MS was used for biomarker analysis.
RESULTS: Reference values are presented for all biomarkers. Results show that gender strongly influences the excretion of each biomarker in the pediatric Fabry cohort, with females having lower urinary levels of all biomarkers. Urinary distribution of lyso-Gb3/related analogues in treated Fabry males was similar to the untreated and treated Fabry female groups in both children and adult cohorts. Children with the late-onset p.N215S mutation had normal urinary levels of Gb3, and lyso-Gb3 but abnormal levels of related analogues.
CONCLUSIONS: In this study, Fabry males and most Fabry females would have been diagnosed using the urinary lyso-Gb3/related analogue profile.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Children; Fabry disease; Globotriaosylceramide; Globotriaosylsphingosine and analogues; Mass spectrometry

Mesh:

Substances:

Year:  2014        PMID: 25149322     DOI: 10.1016/j.cca.2014.08.002

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  19 in total

Review 1.  Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.

Authors:  Malte Lenders; Eva Brand
Journal:  J Am Soc Nephrol       Date:  2018-08-09       Impact factor: 10.121

2.  Relative distribution of Gb3 isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry.

Authors:  Philippe Provençal; Michel Boutin; Shaalee Dworski; Bryan Au; Jeffrey A Medin; Christiane Auray-Blais
Journal:  Bioanalysis       Date:  2016-08-15       Impact factor: 2.681

3.  Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease.

Authors:  Fahad J Alharbi; Shanat Baig; Christiane Auray-Blais; Michel Boutin; Douglas G Ward; Nigel Wheeldon; Rick Steed; Charlotte Dawson; Derralynn Hughes; Tarekegn Geberhiwot
Journal:  J Inherit Metab Dis       Date:  2018-01-02       Impact factor: 4.982

4.  Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.

Authors:  Susana Ferreira; Christiane Auray-Blais; Michel Boutin; Pamela Lavoie; José Pedro Nunes; Elisabete Martins; Scott Garman; João Paulo Oliveira
Journal:  Clin Chim Acta       Date:  2015-06-09       Impact factor: 3.786

Review 5.  Contribution of tandem mass spectrometry to the diagnosis of lysosomal storage disorders.

Authors:  Monique Piraud; Magali Pettazzoni; Pamela Lavoie; Séverine Ruet; Cécile Pagan; David Cheillan; Philippe Latour; Christine Vianey-Saban; Christiane Auray-Blais; Roseline Froissart
Journal:  J Inherit Metab Dis       Date:  2018-03-19       Impact factor: 4.982

Review 6.  Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.

Authors:  Michela Ranieri; Gloria Bedini; Eugenio Agostino Parati; Anna Bersano
Journal:  Curr Treat Options Neurol       Date:  2016-07       Impact factor: 3.598

7.  A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin.

Authors:  Kerri J Kinghorn; Sebastian Grönke; Jorge Iván Castillo-Quan; Nathaniel S Woodling; Li Li; Ernestas Sirka; Matthew Gegg; Kevin Mills; John Hardy; Ivana Bjedov; Linda Partridge
Journal:  J Neurosci       Date:  2016-11-16       Impact factor: 6.167

Review 8.  The benefits and challenges of family genetic testing in rare genetic diseases-lessons from Fabry disease.

Authors:  Dominique P Germain; Sergey Moiseev; Fernando Suárez-Obando; Faisal Al Ismaili; Huda Al Khawaja; Gheona Altarescu; Fellype C Barreto; Farid Haddoum; Fatemeh Hadipour; Irina Maksimova; Mirelle Kramis; Sheela Nampoothiri; Khanh Ngoc Nguyen; Dau-Ming Niu; Juan Politei; Long-Sun Ro; Dung Vu Chi; Nan Chen; Sergey Kutsev
Journal:  Mol Genet Genomic Med       Date:  2021-04-09       Impact factor: 2.183

Review 9.  Biomarkers in Lysosomal Storage Diseases.

Authors:  Joaquin Bobillo Lobato; Maria Jiménez Hidalgo; Luis M Jiménez Jiménez
Journal:  Diseases       Date:  2016-12-17

10.  Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres.

Authors:  Aizeddin A Mhanni; Christiane Auray-Blais; Michel Boutin; Alie Johnston; Kaye LeMoine; Jill Patterson; Johannes M F G Aerts; Michael L West; Cheryl Rockman-Greenberg
Journal:  Mol Genet Metab Rep       Date:  2020-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.